BioNxt Solutions Second Quarter 2024 Earnings: CA$0.009 loss per share (vs CA$0.024 loss in 2Q 2023)
BioNxt Solutions (CSE:BNXT) Second Quarter 2024 Results
Key Financial Results
- Net loss: CA$974.4k (loss narrowed by 59% from 2Q 2023).
- CA$0.009 loss per share (improved from CA$0.024 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioNxt Solutions shares are down 4.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 7 warning signs for BioNxt Solutions (of which 4 make us uncomfortable!) you should know about.
Valuation is complex, but we're here to simplify it.
Discover if BioNxt Solutions might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:BNXT
BioNxt Solutions
Engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland.
Medium-low with weak fundamentals.
